Dr Antje Walz
Vice President Translational Sciences
3T Biosciences GmbH, Basel, Switzerland
From bench to bedside: bringing (precision) medicine to patients with translational modeling
Abstract:
The main question in drug development is to understand which patients may benefit from which drug at which dose and dosing regimen. Before any clinical studies can be conducted in humans with new investigational drugs, the safety and efficacy profile needs to be investigated in nonclinical in vitro and potentially in vivo experiments. The outcome and results are then quantitatively translated to humans to enable the prediction of an efficacious dose and dosing regimen. A suited methodology for this is translational modeling and simulation (M&S) which allows to bridge pharmacological activity related to safety and efficacy from nonclinical space to the clinic trials and support dose selection throughout development and eventually improve the success rate in patients (Lave et al., 2016). The concepts of translational M&S will be illustrated with a few case examples. An outlook will be provided on how this can be further applied to optimize the therapeutic index on an individual patient basis with precision dosingD.
Key references:
Lavé T, Caruso A, Parrott N, Walz A. Translational PK/PD modeling to increase probability of success in drug discovery and early development. Drug Discov Today Technol. 2016 Sep-Dec;21-22:27-34. doi: 10.1016/j.ddtec.2016.11.005. .
Biography:
Antje Walz is a Vice President of Translational Sciences at 3T Biosciences, prior to that she worked as an expert scientist at F. Hoffmann-La Roche . She is an experienced drug developer with 20 years of experience in Biotech and Pharmaceutical Industry focussing to bring different modalities for various therapeutic indications from bench to bedside. Her main area of expertise is in translational modeling & simulation applied from basic research to clinical development, predominantly in oncology. Her research interest is in the area of precision dosing and to develop dose optimization strategies that enhance the risk/benefit profile of the individual patient. She received a Diploma in 1998 and a PhD (Dr. rer nat) in 2002 both in Biology from the University of Konstanz, Germany.
Return to School information